An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...
The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...
Moderna and Merck said on Wednesday (August 19) that a personalized mRNA cancer vaccine reduced the risk of recurrence and ...
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Al Jazeera on MSN
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna’s mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results